How do you collaborate with other multidisciplinary clinicians, such as cardiologists, nephrologists, endocrinologists, primary care, to ensure coordinated CKD identification and follow-up?
What advice would you like to share with colleagues about implementing both uACR and eGFR testing to support earlier CKD diagnosis and cardiovascular risk management in clinical practice?

Led by the moderator, the experts conclude by addressing the challenge of maintaining a continuum of care between infrequent clinical visits, identifying the EHR as the critical "common denominator" for aligning primary care, cardiology, and endocrinology on a unified plan. Dr. Kushner stresses the importance of explicit clinician-to-clinician communication and detailed "SOAP" plan documentation to prevent therapeutic inertia during the months between specialist consultations. A major highlight of the discussion is the expanded role of the pharmacist in executing "de-congestion" strategies, such as remote medication titration, which allows physicians to focus on diagnostic complexity while ensuring patients reach guideline-directed doses.

The panel also underscores the necessity of patient empowerment, suggesting that showing a patient their position on the KDIGO heat map can bridge the literacy gap and foster shared decision-making. Final pearls from the experts reinforce that the "science is clear" and the current therapeutic armamentarium offers a unique opportunity to change the trajectory of CKD if caught early. By embracing a "know your numbers" campaign for uACR and fostering a community of healthcare responsibility, the panelists argue that clinicians can meaningfully delay or even prevent the progression to end-stage renal disease, providing patients with a significantly higher quality of life.

Thank you for watching this Peer Exchange series on chronic kidney disease and cardiovascular risk. Please subscribe to our newsletter for information on upcoming video series.